Linagliptin-metformin combo boosts glucose control in type 2 diabetes

05/31/2012 | Endocrine Today

A higher-dose combination of linagliptin and metformin fared better than a high-dose metformin-only treatment in lowering blood glucose levels in patients with type 2 diabetes, a study presented at the American Association of Clinical Endocrinologists meeting showed. The combination treatment was also very well-tolerated in patients over 18 months, a researcher said.

View Full Article in:

Endocrine Today

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX